Boston, Massachusetts, United States, October 28, 2026
HotSpot Therapeutics, Inc. has announced plans to present new preclinical research on HST-2011, its investigational small-molecule inhibitor of interferon regulatory factor 5 (IRF5), at the American College of Rheumatology (ACR) Convergence 2026 annual meeting. The presentation will highlight the compound’s effects on innate and adaptive immune pathways, providing further scientific support for its potential development in systemic lupus erythematosus (SLE) and other autoimmune diseases. The poster is scheduled for November 8, 2026, during the conference, which will take place from November 6 to 11 in Orlando, Florida. The announcement represents a research milestone for HotSpot as it advances an approach designed to selectively target IRF5, a protein involved in regulating immune responses.
HST-2011 Targets IRF5 to Modulate Immune Responses
HST-2011 is an investigational, non-covalent, non-degrading, allosteric small-molecule inhibitor of IRF5. This transcription factor plays an important role in controlling several biological processes associated with the immune system, acting as a key regulator of both innate and adaptive immunity. These immune pathways help the body recognize and respond to threats, but abnormal or excessive immune activity can contribute to autoimmune and inflammatory disorders. IRF5 has attracted research interest because genetic association studies have identified links between the gene and multiple immune-mediated conditions, including systemic lupus erythematosus, Sjögren’s disease, rheumatoid arthritis, systemic sclerosis, and myositis. HotSpot is investigating whether selective inhibition of IRF5 can influence these disease-associated immune pathways. Unlike approaches that aim to eliminate or degrade a target protein, HST-2011 is designed to modulate IRF5 activity through an allosteric mechanism. This strategy is intended to influence protein function by interacting with a regulatory site rather than relying on a conventional active site.
Smart Allostery Platform Supports Drug Discovery
The discovery of HST-2011 was enabled by HotSpot Therapeutics’ proprietary Smart Allostery™ platform, which is designed to identify naturally occurring regulatory pockets, also known as hotspots, on proteins. According to the company, traditional small-molecule approaches to targeting IRF5 have faced challenges because the protein lacks a conventional active site that can be readily addressed using standard drug-discovery methods. HotSpot’s platform combines computational approaches, artificial intelligence-driven data analysis, pharmacology tools, and medicinal chemistry to identify and develop molecules that interact with these regulatory pockets. Using this approach, the company reports that it has discovered HST-2011 as a potent and selective IRF5 inhibitor. The programme reflects a broader drug-discovery strategy focused on targeting proteins that have historically been difficult to modulate with small molecules. By investigating allosteric regulation, HotSpot aims to expand the range of potential drug targets available for autoimmune and inflammatory disease research. The company is also building a pipeline of allosteric therapies intended to address conditions involving abnormal immune activity.
Advertisement
ACR Convergence 2026 to Feature Preclinical Findings
The research will be presented under the title “HST-2011, a Potent, Selective IRF5 Small Molecule Inhibitor, Enables Coordinated Inhibition of Innate and Adaptive Immune Responses in SLE.” The poster has been assigned number 0146 and will appear in the category B Cell Biology & Targets in Autoimmune & Inflammatory Disease. The scheduled session is Sunday, November 8, from 10:30 a.m. to 12:30 p.m. Eastern Time, at location WB1&2. The presentation is expected to provide additional details on the preclinical investigation of HST-2011 and its effects on immune-response pathways relevant to SLE. ACR Convergence brings together researchers, clinicians, and healthcare professionals working in rheumatology and related areas, providing a scientific forum for discussing developments in autoimmune disease research and treatment approaches.
The presentation marks an important opportunity for HotSpot Therapeutics to share its early research with the rheumatology community. HST-2011 remains in preclinical development, and further studies will be required to establish its safety, efficacy, and suitability for clinical testing. The findings should therefore be considered early-stage scientific evidence rather than confirmation of therapeutic benefit in patients. If subsequent research supports the programme, selective IRF5 inhibition could provide a potential avenue for investigating treatments for SLE and other immune-mediated diseases. The upcoming presentation will contribute to scientific discussion around targeted immune modulation and allosteric drug discovery.
Source: HotSpot Therapeutics press release
